Can Central Government Ban Fixed Dose Combinations Without DTAB Consultation? Supreme Court Clarifies
Union of India and Anr. vs Pfizer Limited and Ors.
Listen to this judgment
• 4 min readKey Takeaways
• A court cannot require consultation with the DTAB before the Central Government exercises powers under Section 26A of the Drugs Act.
• Section 26A allows the Central Government to prohibit drugs based on public interest without mandatory DTAB consultation.
• The Central Government's satisfaction regarding drug safety can be based on relevant material, even without DTAB input.
• Judicial review of the Central Government's decision under Section 26A is limited to the existence of relevant material.
• Previous judgments suggesting mandatory DTAB consultation under Section 26A are not binding as they lack focused argument.
Introduction
The Supreme Court of India, in its judgment dated December 15, 2017, addressed the critical issue of whether the Central Government is required to consult the Drugs Technical Advisory Board (DTAB) before exercising its powers under Section 26A of the Drugs and Cosmetics Act, 1940. This ruling has significant implications for the regulation of Fixed Dose Combinations (FDCs) in India, particularly in light of concerns regarding their safety and efficacy.
Case Background
The case arose from a series of appeals and transfer petitions concerning the interpretation of Section 26A of the Drugs and Cosmetics Act. The Delhi High Court had previously ruled that prior consultation with the DTAB was a mandatory condition before the Central Government could exercise its powers under Section 26A. This decision was contested by the Union of India, which argued that such consultation was not explicitly required by the statute.
The context of the case involved the proliferation of FDCs in the Indian market, many of which had not been tested for safety or efficacy. The Parliamentary Standing Committee on Health and Family Welfare had raised concerns about the risks posed by unapproved FDCs, leading to the Central Government's actions to regulate these combinations.
What The Lower Authorities Held
The learned single Judge of the Delhi High Court held that the mandatory condition precedent for the exercise of power under Section 26A was the prior consultation with the DTAB. This ruling diverged from earlier judgments by the Karnataka and Madras High Courts, which had concluded that such consultation was not necessary. The Delhi High Court's decision was based on the premise that the DTAB's expertise was essential for ensuring the safety and efficacy of drugs before any prohibition could be enacted.
The Court's Reasoning
The Supreme Court, led by Justice R.F. Nariman, examined the legislative intent behind Section 26A and the broader framework of the Drugs and Cosmetics Act. The Court noted that Section 26A was introduced by an amendment in 1982, and unlike other sections of the Act that explicitly required consultation with the DTAB, Section 26A did not contain such a provision. This omission was interpreted as a deliberate choice by Parliament, indicating that the Central Government could exercise its powers under Section 26A without mandatory DTAB consultation.
The Court emphasized that the Central Government's satisfaction regarding the risks associated with a drug could be based on relevant material, including expert reports from other countries or findings from district authorities. The judgment highlighted that the power granted under Section 26A was broad and should not be unduly restricted by imposing additional requirements not present in the statute.
Statutory Interpretation
The Supreme Court's interpretation of Section 26A underscored the importance of legislative intent in statutory construction. The Court distinguished between legislative powers and administrative powers, asserting that the Central Government's authority under Section 26A was legislative in nature. Consequently, the requirement for natural justice, such as consultation with the DTAB, was not applicable in this context.
The Court also addressed arguments that previous judgments had established a precedent for mandatory DTAB consultation. It clarified that such references were not binding as they lacked a focused argument on the necessity of consultation under Section 26A. The judgment reinforced the principle that courts should not supply omissions in legislation and should respect the clear language of the statute.
Why This Judgment Matters
This ruling is significant for several reasons. Firstly, it clarifies the scope of the Central Government's powers under Section 26A, allowing for more agile regulatory responses to public health concerns regarding FDCs. By affirming that the government can act without mandatory DTAB consultation, the Court has potentially expedited the process of banning unsafe drugs, thereby protecting public health.
Secondly, the judgment sets a precedent for the interpretation of legislative intent in statutory provisions. It emphasizes the need for courts to adhere to the explicit language of the law and to avoid imposing additional requirements that are not present in the statute.
Final Outcome
The Supreme Court ultimately set aside the Delhi High Court's judgment, ruling that the Central Government's actions under Section 26A did not require prior consultation with the DTAB. The Court directed that the cases concerning the banned FDCs be referred to the DTAB for further examination, ensuring that the regulatory process remains robust while respecting the legislative framework.
Case Details
- Citation: 2017 INSC 1248
- Court: In The Supreme Court Of India
- Date of Judgment: December 15, 2017
